CAT Commences NASDAQ Trading

Cambridge Antibody Tech Group PLC
11 June 2001

01/CAT/11

Page 1 of 2

FOR IMMEDIATE RELEASE

07.00 BST, 02.00 EST Monday 11 June 2001


For Further Information Contact:

Cambridge Antibody Technology               Square Mile BSMG Worldwide (Europe)

Tel: [phone]                   Tel: [phone]

David Chiswell, CEO                         Kevin Smith

John Aston, Finance Director                Graham Herring

Rowena Gardner, Head of Corporate
Communications


                                            BMC Communications/The Trout Group
                                            (USA)

                                            Tel: [phone]

                                            Brad Miles, ext 17 (media)

                                            Brandon Lewis, ext.15 (investors)





 CAMBRIDGE ANTIBODY TECHNOLOGY ADRs TO COMMENCE TRADING ON US NASDAQ NATIONAL
                                    MARKET




Melbourn, UK... Cambridge Antibody Technology (LSE: CAT) announced that its
registration statement with the SEC is effective and that its shares are
scheduled to begin trading on Monday 11 June 2001 on the US NASDAQ National
Market under the ticker symbol 'CATG'. Trading will be in the form of American
Depository Receipts ('ADRs)', each ADR representing one ordinary share.
Depository bank for the ADR program is the Bank of New York.

The NASDAQ listing is a Level Two ADR listing.

Dr. David Chiswell, Chief Executive Officer of CAT, commented, 'Our listing on
the US NASDAQ National Market will help raise CAT's visibility in the US in
both the commercial and financial arenas, expand and support CAT's growing US
investor base and help to move the company forward as a global biotechnology
company, leading the way in the discovery and development of human monoclonal
antibody therapeutics.'



                                    -ENDS-






Page 2 of 2

Notes to Editors:

Cambridge Antibody Technology (LSE: CAT)

CAT is a UK biotechnology company using its proprietary technologies in human
monoclonal antibodies for drug discovery and drug development. Based in
Melbourn, 10 miles south of Cambridge, England, CAT currently employs around
230 people.

CAT raised £41m in its IPO in March 1997 and £93m (£89.4m net of expenses) in
a secondary offering in March 2000.

CAT has an advanced platform technology for rapidly isolating human monoclonal
antibodies, primarily using phage display technology. CAT's library currently
incorporates around 100 billion distinct antibodies. This library forms the
basis for the company's strategy to develop a portfolio of clinical
development programmes and for discovering new drug leads using functional
genomics. Four human therapeutic antibodies developed by CAT are at various
stages of clinical trials.

CAT works in partnership with other companies at all stages of the drug
discovery and development process. CAT's collaborations, past and present,
include: AstraZeneca, Eli Lilly, Genentech, Genetics Institute, Genzyme, Human
Genome Sciences, Immunex, Knoll Pharmaceuticals (a subsidiary of Abbott
Laboratories), Oxford GlycoSciences, Pharmacia, Pfizer, Wyeth-Ayerst, Xerion
and Zyomyx.



This press release contains statements about Cambridge Antibody Technology
Group plc (CAT) that are forward looking statements. All statements other than
statements of historical facts included in this press release may be forward
looking statements

These forward looking statements are based on numerous assumptions regarding
CAT's present and future business strategies and the environment in which CAT
will operate in the future. Certain factors that could cause CAT's actual
results, performance or achievements to differ materially from those in the
forward looking statements include: market conditions, CAT's ability to enter
into and maintain collaborative arrangements, success of product candidates in
clinical trials, regulatory developments and competition.